Another autoimmune CAR-T death; Treasury zeroes in on China deals
A patient who received Bristol Myers’ zola-cell died 44 days later. Elswehere, Gilead paid nearly $1.3 billion for a potential threat to J&J’s newly approved psoriasis pill.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.